Atossa Therapeutics, Inc. (ATOS)
ATOS Stock Price Chart
Explore Atossa Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze ATOS price movements and trends.
ATOS Company Profile
Discover essential business fundamentals and corporate details for Atossa Therapeutics, Inc. (ATOS) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
8 Nov 2012
Employees
15.00
CEO
Steven C. Quay FCAP,
Description
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201, an inhalation therapy to improve lung function in severely ill and hospitalized COVID-19 patients; AT-301, a proprietary drug candidate for nasal administration in patients diagnosed with COVID-19; and immunotherapy/chimeric antigen receptor therapy programs for the treatment of breast cancer. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.
ATOS Financial Timeline
Browse a chronological timeline of Atossa Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 May 2026
Upcoming earnings on 11 Nov 2025
EPS estimate is -$0.07.
Earnings released on 12 Aug 2025
EPS came in at -$0.07 falling short of the estimated -$0.06 by -16.67%.
Earnings released on 13 May 2025
EPS came in at -$0.05 surpassing the estimated -$0.06 by +16.67%.
Earnings released on 25 Mar 2025
EPS came in at -$0.05 surpassing the estimated -$0.06 by +16.67%.
Earnings released on 12 Nov 2024
EPS came in at -$0.05 surpassing the estimated -$0.06 by +16.67%.
Earnings released on 12 Aug 2024
EPS came in at -$0.05 matching the estimated -$0.05.
Earnings released on 1 Apr 2024
EPS came in at -$0.06 falling short of the estimated -$0.05 by -20.00%.
Earnings released on 27 Mar 2024
EPS came in at -$0.09 falling short of the estimated -$0.06 by -50.00%, while revenue for the quarter reached $18.00K .
Earnings released on 13 Nov 2023
EPS came in at -$0.05 surpassing the estimated -$0.07 by +28.57%.
Earnings released on 14 Aug 2023
EPS came in at -$0.06 matching the estimated -$0.06.
Earnings released on 15 May 2023
EPS came in at -$0.05 surpassing the estimated -$0.06 by +16.67%.
Earnings released on 22 Mar 2023
EPS came in at -$0.06 falling short of the estimated $0.06 by -200.00%.
Earnings released on 7 Nov 2022
EPS came in at -$0.06 matching the estimated -$0.06.
Earnings released on 8 Aug 2022
EPS came in at -$0.05 surpassing the estimated -$0.06 by +16.67%.
Earnings released on 9 May 2022
EPS came in at -$0.04 surpassing the estimated -$0.05 by +20.00%.
Earnings released on 28 Feb 2022
EPS came in at -$0.04 falling short of the estimated -$0.04 by -11.11%.
Earnings released on 15 Nov 2021
EPS came in at -$0.04 falling short of the estimated -$0.04 by -11.11%.
Earnings released on 13 Aug 2021
EPS came in at -$0.06 falling short of the estimated -$0.04 by -71.43%.
Earnings released on 14 May 2021
EPS came in at -$0.04 surpassing the estimated -$0.05 by +20.00%.
Earnings released on 31 Mar 2021
EPS came in at -$0.89 .
Earnings released on 13 Nov 2020
EPS came in at -$0.34 matching the estimated -$0.34.
ATOS Stock Performance
Access detailed ATOS performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.